Ascendis Pharma AS logo

Ascendis Pharma AS(ASND)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 11 days
PROFIT SINCE LAST BUY
+9.6% ▲
LAST CLOSE
$275.39
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ASND

11/13/2026: ASND (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Ascendis Pharma AS is a commercial-stage biopharmaceutical company leveraging its proprietary TransCon platform to develop specialized treatments for rare endocrine diseases. The company's primary strength lies in the successful commercialization of Skytrofa and a robust pipeline addressing high unmet medical needs. Key growth opportunities stem from label expansions and new product rollouts across global markets, though execution risks and ongoing operating expenses remain key considerations. The stock is best suited for growth-oriented investors willing to monitor regulatory milestones, reimbursement trends, and commercial scaling progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitAscendis delivers high revenue growth rates driven by the commercial scaling of its rare disease portfolio.
Momentum investorStrong fit while signal remains positiveStock price reactions to regulatory decisions and commercial milestones frequently create strong upward momentum trends.
Value investorWeak fitThe company trades on pipeline potential and revenue growth rather than near-term earnings or book value.
Dividend investorWeak fitAscendis does not pay dividends, directing all cash flow toward clinical development and commercial expansion.
Low-risk investorWeak fitHigh clinical, regulatory, and price volatility typical of clinical-stage and commercial biotech companies creates substantial risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech market sentiment and binary clinical trial or regulatory events trigger sharp share price swings.
Valuation riskMedium / highValuations are heavily dependent on long-term cash flow assumptions for pipeline products.
Competition risk (rare disease and endocrinology)MediumWell-capitalized pharmaceutical rivals continually attempt to develop alternative long-acting therapies.
Business qualityMedium / highProprietary TransCon technology creates a defensible scientific moat, though commercial execution is critical.
Dividend incomeLow / noneNo dividend is paid, offering zero income return for yield-focused investors.
Execution riskHighCommercial uptake, market access, and global reimbursement negotiations dictate top-line success.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 18.06B USD
Price to earnings Ratio 18.11
1Y Target Price 315.2
Price to earnings Ratio 18.11
1Y Target Price 315.2
Volume (30-day avg) 726.9K shares
Beta 0.48
52 Weeks Range 188.08 - 282.15
Updated Date 11/15/2026
52 Weeks Range 188.08 - 282.15
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 15.21

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steady Uptrend
PRICE PATH

Steady Uptrend

The stock demonstrates consistent and steady upward price momentum.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -44.61%
Avg. Invested days 29
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ASND receives a 3-star rating, supported by solid company fundamentals, solid quantitative characteristics, and strong analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
ASND has solid overall fundamentals (4 stars), with moderate financial health, strong growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+42.1%) and solid cash generation (FCF margin 6.3%) are partially offset by weak profitability (net margin -31.7%), very low insider ownership of 0.90%.

Financial Health Rating

★★★★★
ASND's financial health is supported by moderate liquidity, including working-capital and asset support (WC/assets 3.0%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is ASND's strongest growth driver at +114.2% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+90.2%, strong) and earnings growth (+42.1%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 101.0% and approximately 99.9% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.90%, which materially reduces the ownership score.

Top 5 Institutional Investors

Frazier Life Sciences Management, L.P. 0.34%
Neuberger Berman Group LLC 0.22%
ODDO BHF Asset Management SAS 0.20%
Quadrature Capital Limited 0.06%
Ferguson Wellman Capital Management, Inc 0.00%

Unit Economics (Per $1K Revenue)

★★★★★
ASND generates approximately $851 of gross profit, $-189 of operating income, and $63 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses explain the 2-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -7.23% (Tax Credit)

Quantitative Style Profile

★★★★★
ASND has a high-quality, large-cap, liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Quality TiltLow VolatilityLarge / Mega Cap StabilityShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Skytrofa Product SalesGlobal commercial sales of Skytrofa for pediatric growth hormone deficiency.This is the core revenue engine currently driving the company's financial growth.
Endocrinology Pipeline CommercializationUpcoming and newly approved treatments like Yorvipath for hypoparathyroidism.Represents the next wave of diversification and revenue expansion beyond growth hormone products.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-12
When Before Market
Estimate 1.13
Actual 1.24

Profitability

Profit Margin 72.88%
Operating Margin (TTM) 30.94%

Management Effectiveness

Return on Assets (TTM) 12.99%
Return on Equity (TTM) 132.2%

Valuation

Trailing PE 18.11
Forward PE 23.36
Enterprise Value 17.49B
Price to Sales(TTM) 15.02
Enterprise Value 17.49B
Price to Sales(TTM) 15.02
Enterprise Value to Revenue 13.16
Enterprise Value to EBITDA 44.67
Shares Outstanding 65.60M
Shares Floating 65.56M
Shares Outstanding 65.60M
Shares Floating 65.56M
Percent Insiders 0.9
Percent Institutions 101

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.